Tomagan John Michael P, Lo Charles Cedy C, Granda Alyssa Anne E, Panaligan Mae M, Yu Candice Chin-Chin C, Vera Cruz Veronica T
Department of Radiotherapy, Jose R. Reyes Memorial Medical Center, Manila, Philippines.
Department of Obstetrics and Gynecology, Section of Gynecologic Oncology and Trophoblastic Disease Jose R. Reyes Memorial Medical Center, Manila, Philippines.
Gynecol Oncol Rep. 2024 Jul 26;55:101469. doi: 10.1016/j.gore.2024.101469. eCollection 2024 Oct.
Managing endometrial cancer with suspected or gross cervical involvement lacks a standard approach. This study evaluated outcomes in patients with cervical and/or parametrial involvement treated with neoadjuvant radiation followed by hysterectomy.
Fourteen patients from 2007 to 2022 with locally advanced endometrial cancer and cervical and/or parametrial involvement were retrospectively analyzed. They received neoadjuvant external beam radiotherapy (45-50.4 Gy in 25-30 fractions) and high-dose rate brachytherapy (5.5-7.0 Gy per fraction in 3-4 fractions), followed by extrafascial hysterectomy. Clinical data, pathologic response, and survival outcomes were assessed, along with factors associated with pathologic response.
Most patients (86%) had stage III disease with cervical extension, 93% had parametrial involvement, and 14% had nodal involvement. Chemotherapy was given to 86% either concurrently or adjuvantly. Post-surgery, 86% had no pathologic cervical involvement, and 93% had negative surgical margins. Pathologic complete response was seen in 43%. Locoregional recurrence occurred in 14%. Median follow-up was 30 months, with recurrence-free survival and overall survival rates of 86% and 100%, respectively. Lower grade tumors significantly correlated with pathologic complete response (Φ = 0.72, p = 0.026). No significant correlation was found between pathologic complete response and other factors. No late grade 3-4 toxicities were reported.
Neoadjuvant radiation followed by hysterectomy, with or without chemotherapy, is a viable strategy for managing endometrial cancer with cervical and/or parametrial involvement. This approach enhances resectability, yielding high rates of pathologic complete response and negative resection margins, showing promise for this challenging patient group.
对于怀疑有宫颈受累或肉眼可见宫颈受累的子宫内膜癌,目前缺乏标准的治疗方法。本研究评估了接受新辅助放疗后行子宫切除术的宫颈和/或宫旁受累患者的治疗结果。
回顾性分析了2007年至2022年期间14例局部晚期子宫内膜癌且伴有宫颈和/或宫旁受累的患者。他们接受了新辅助外照射放疗(25 - 30次分割,共45 - 50.4 Gy)和高剂量率近距离放疗(3 - 4次分割,每次分割5.5 - 7.0 Gy),随后行筋膜外子宫切除术。评估了临床数据、病理反应和生存结果,以及与病理反应相关的因素。
大多数患者(86%)为Ⅲ期疾病伴宫颈扩展,93%有宫旁受累,14%有淋巴结受累。86%的患者接受了同步或辅助化疗。术后,86%的患者宫颈无病理受累,93%的患者手术切缘阴性。病理完全缓解率为43%。局部区域复发率为14%。中位随访时间为30个月,无复发生存率和总生存率分别为86%和100%。低级别肿瘤与病理完全缓解显著相关(Φ = 0.72,p = 0.026)。未发现病理完全缓解与其他因素之间存在显著相关性。未报告3 - 4级晚期毒性反应。
新辅助放疗后行子宫切除术,无论是否联合化疗,都是治疗伴有宫颈和/或宫旁受累的子宫内膜癌的可行策略。这种方法提高了可切除性,产生了较高的病理完全缓解率和阴性切缘率,对这一具有挑战性的患者群体显示出前景。